Stablecoin Development Corporation (NYSEAM: SDEV)
Health Care · Pharmaceuticals · US
$1.14
+10.68% today · -74.8% 1Y
Stablecoin Development Corporation (NYSEAM: SDEV) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $57.70M and employs 4 people.
Over the last twelve months the share price has lost 74.8%, trading between 0.93 and 99.75.
Tweenvest scores Stablecoin Development Corporation across four factors: quality 52/100, value 70/100. Its strongest factor is value.
SDEV price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $57.70M
- Revenue (TTM)
- $-23.29M
- P/E
- 0.23
- EPS
- 4.96
- Dividend yield
- —
- Beta (5Y)
- 0.09
- 52-week high
- $99.75
- 52-week low
- $0.93
- Avg volume (3M)
- —
- Shares outstanding
- 50.62M
- Employees
- 4
- Next earnings
- —
About Stablecoin Development Corporation
Stablecoin Development Corp. specializes in manufacturing and distributing eye and skin health solutions that have undergone rigorous scientific development and proven efficacy in clinical settings. Their product portfolio features prominent brands such as Avenova, NeutroPhase, and DERMAdoctor. This enterprise was established on January 19, 2000, and its main office is situated in Emeryville, California.
- ISIN
- US66987P5089
- Founded
- 2000
- Listed since
- Oct 26, 2007
- Exchange
- NYSE American LLC
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.11T | $1,247.58 | +0.05% |
| Johnson & JohnsonNYSE: JNJ | $658.00B | $271.39 | -0.60% |
| Merck & Co., Inc.NYSE: MRK | $371.70B | $151.23 | +0.38% |
| Roche Holding AGSWX: ROP | $368.80B | CHF371.10 | +0.19% |
| Novartis AGSWX: NOVN | $300.52B | CHF126.76 | -0.52% |
| AstraZeneca PLCLSE: AZN | $256.25B | £121.32 | +0.18% |
| Novo Nordisk A/SCPSE: NOVO B | $206.64B | Dkr299.25 | -0.53% |
| Pfizer Inc.NYSE: PFE | $159.42B | $28.02 | +0.18% |
Figures last refreshed Aug 18, 2026.